一、2025年度主要财务数据和指标 证券代码：688079 证券简称：美迪凯 公告编号：2026-006 杭州美迪凯光电科技股份有限公司 2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以公司2025年年 度的定期报告为准，提请投资者注意投资风险。 单位：万元 ■ 注：1.本报告期初数同法定披露的上年年末数。 2.上述财务数据及指标为未经审计的合并报表数据，最终数据以公司2025年年度报告中披露数据为准。 二、经营业绩和财务状况情况说明 （一）报告期的经营情况以及财务状况 公司2025年度实现营业收入66,438.70万元，较上年同期增加17,887.58万元，同比增长36.84%；实现归 属于母公司所有者的净利润-15,501.45万元，较上年同期亏损扩大5,316.87万元；实现归属于母公司所有 者的扣除非经常性损益的净利润-15,786.65万元，较上年同期亏损扩大6,477.93万元。 报告期末公司总资产337 ...

Group 1: Transaction Overview - The company plans to introduce strategic investor Zhejiang Fuzhe Shaoxin Integrated Circuit Industry Fund Partnership (Limited Partnership) through its subsidiary Zhejiang Meidikai Optical Semiconductor Co., Ltd. [2] - The board of directors approved the proposal for capital increase and share expansion on December 10, 2025, and the relevant agreements have been signed [3]. Group 2: Transaction Progress - As of the announcement date, the company and related parties have signed the capital increase agreement and shareholder agreement, with a total cash capital increase of RMB 200 million received [3]. - Following the capital increase, the registered capital of the optical semiconductor company will increase from RMB 1,008,888,889 to RMB 1,101,447,503, and the company's shareholding will change to 82.44% [3]. Group 3: Performance Forecast - For the fiscal year 2025, the company expects to achieve approximately RMB 664.26 million in revenue, a year-on-year increase of 36.82% [8]. - The company anticipates a net loss attributable to shareholders of approximately RMB -154.41 million, a decrease of RMB 52.57 million compared to the previous year [8]. - EBITDA is projected to be around RMB 65.29 million, reflecting a year-on-year increase of 19.62% [8]. Group 4: Revenue Growth Factors - The revenue increase is attributed to higher sales in semiconductor packaging and testing, as well as new product launches contributing to additional revenue [14]. - Specific revenue contributions include an increase of approximately RMB 94.32 million from semiconductor packaging and testing and RMB 88.90 million from semiconductor acousto-optics [14]. Group 5: Cost and Expense Increases - The company has incurred higher costs due to stock incentive plans, increased interest expenses from larger borrowings, and rising depreciation costs from fixed asset investments [15][16]. - Research and development expenses have also increased, reflecting the company's commitment to new technologies and products [16].

Core Viewpoint - Meidike announced a projected loss for 2025 despite a revenue increase of approximately 6.64 billion yuan, marking a year-on-year growth of 36.82%. However, the net profit attributable to shareholders is expected to be around -1.54 billion yuan, worsening from -1.02 billion yuan in the previous year, with a non-recurring net profit of about -1.57 billion yuan, indicating a further decline in profitability [1]. Revenue and Business Performance - The revenue growth is attributed to the collaborative efforts across multiple business segments, with semiconductor packaging and testing sales expected to increase by 94.32 million yuan and semiconductor optoelectronics sales by 88.90 million yuan. Additionally, the company anticipates a revenue increase of 10.97 million yuan from the mass production of semiconductor process bonding prisms starting in November 2025, and 4.26 million yuan from small-scale production of MEMS devices [2]. Cost and Expense Analysis - The primary reason for the projected losses is attributed to rising costs and expenses. The company incurred approximately 43.21 million yuan in share-based payment expenses due to an equity incentive plan. Interest expenses rose to about 40.47 million yuan due to increased borrowing for substantial fixed asset investments. Depreciation expenses increased to approximately 205 million yuan, and labor costs rose to about 188 million yuan as projects entered mass production. Additionally, R&D expenses amounted to around 137 million yuan [2]. Client Relationships - Major downstream clients contributing significantly to the company's revenue include Huida Technology, Kyocera Group, and New Sound Semiconductor. The company has also established business partnerships with Canon, Nikon, AMS, Sunny Optical, Hikvision, Foxconn, Panasonic, Ricoh, Sony, AGC, and Keyence [3]. Future Development Directions - Looking ahead to 2026, the company has identified two core development directions. Firstly, it plans to increase R&D investment and production capacity for MEMS devices, particularly focusing on the industrialization of MicroLED and non-cooling infrared sensor chips, driven by the growing demand in humanoid robotics and AI sectors. Secondly, it aims to deepen its focus on the innovative intersection of semiconductors and optics, consolidating its core advantages in products like ultrasonic fingerprint recognition chips and image sensor optical layers [4]. Shareholder Actions - A significant shareholder, Hong Kong Fengsheng Jiamei (International) Investment Co., Ltd., plans to reduce its stake by up to 1% of the total share capital, approximately 4.11 million shares, starting from February 2, 2026. This shareholder has already reduced its holdings by about 12.20 million shares, representing 3% of the total share capital over the past 12 months [4].

Core Viewpoint - Medike (688079.SH) expects a significant increase in revenue for 2025, while net profit is projected to decline, indicating a mixed financial outlook for the company [1] Financial Projections - The company anticipates achieving an operating revenue of approximately 664.257 million yuan in 2025, representing an increase of about 178.746 million yuan or 36.82% year-on-year [1] - The projected net profit attributable to the parent company is expected to be around -154.414 million yuan, a decrease of approximately 52.568 million yuan compared to the previous year [1] - The net profit attributable to the parent company, after deducting non-recurring gains and losses, is estimated to be around -156.947 million yuan, reflecting a decline of about 63.860 million yuan year-on-year [1] Revenue Drivers - The increase in revenue is primarily driven by a rise in semiconductor packaging and testing sales, which are expected to increase by approximately 94.322 million yuan [1] - Sales from semiconductor acousto-optic products are projected to rise by about 88.898 million yuan [1] - The company will begin mass production and delivery of semiconductor process bonding prisms in November 2025, contributing an additional revenue of around 10.969 million yuan [1] - Small-scale production of MEMS devices (MicroLED, uncooled infrared) is expected to generate an increase in sales revenue of approximately 4.256 million yuan [1]

Core Viewpoint - Medike (688079.SH) plans to issue A-shares to specific investors, aiming to raise up to 700 million yuan, despite facing significant financial losses in recent years [1] Group 1: Fundraising Plan - The company intends to issue shares to no more than 35 qualified investors, with a maximum of 123 million shares to be issued [1] - The total amount to be raised is capped at 700 million yuan, with 300 million yuan allocated for MEMS device optical system manufacturing, 200 million yuan for semiconductor process bonding prism industrialization, and the remaining 200 million yuan for working capital [1] Group 2: Financial Performance - The company's financial performance has been under pressure, reporting a net profit of 22.09 million yuan in 2022, followed by losses of 84.45 million yuan in 2023, 101.84 million yuan in 2024, and 81.77 million yuan in the first nine months of 2025 [1] - Based on data from the first three quarters of 2025, the company anticipates continued losses for the entire year [1] Group 3: Previous Fundraising Project Performance - The effectiveness of the previous fundraising projects has been disappointing, with the optical optoelectronic component production base project reporting a cumulative loss of 64.85 million yuan as of September 30, 2025, falling short of the promised 283.07 million yuan [1] - The production capacity utilization rate for this project is only 48.56%, primarily due to the project not reaching full capacity [1]

Core Viewpoint - Meidike (688079.SH) has disclosed a plan for a private placement of A-shares for the year 2025, targeting specific qualified investors, with a total fundraising amount not exceeding RMB 700 million [1][2]. Summary by Sections Issuance Details - The private placement will involve no more than 35 specific investors, including various financial institutions and qualified individual investors [1]. - The issuance price will be set at no less than 80% of the average trading price over the previous 20 trading days prior to the pricing date [1][2]. - The type of shares issued will be domestic listed RMB ordinary shares (A-shares) with a par value of RMB 1.00 per share [2]. Fundraising and Investment Plans - The total number of shares to be issued will not exceed 30% of the company's total share capital prior to the issuance, amounting to a maximum of 122,577,359 shares [2]. - The total fundraising amount is capped at RMB 700 million, which will be allocated to three main projects: 1. MEMS device optical system manufacturing project: RMB 300 million 2. Semiconductor process bonding prism industrialization project: RMB 200 million 3. Supplementing working capital: RMB 200 million [2][3]. Shareholder Structure - The actual controller of the company is Ge Wenzhi, who holds 0.42% of the shares directly and controls 54.88% indirectly, maintaining control post-issuance [4]. - The issuance will not alter the control structure of the company, as Ge Wenzhi's shareholding will remain at 42.53% after the issuance, assuming no participation in the subscription [4]. Financial Performance - For the third quarter of 2025, the company reported revenue of RMB 160.42 million, a year-on-year increase of 26.91%, but a net loss attributable to shareholders of RMB -31.13 million [6][7]. - Year-to-date revenue reached RMB 451.13 million, reflecting a 32.04% increase, with a net loss of RMB -81.77 million [6][7]. - In 2023, the company experienced a revenue decline of 22.48%, with a net loss of RMB -84.45 million [8].

Core Viewpoint - The company, MediKey (688079.SH), plans to issue shares to specific investors to raise a total of no more than 700 million yuan, with the net proceeds intended for investment in various projects and working capital [1] Group 1 - The total amount to be raised through the share issuance is capped at 700 million yuan, including the principal [1] - The net proceeds will be allocated to the MEMS device optical system manufacturing project, the semiconductor process bonding prism industrialization project, and to supplement working capital [1]

Core Viewpoint - Meidike (688079.SH) announced plans to issue shares to specific investors, aiming to raise no more than 700 million yuan, which will be used for various projects and working capital [1] Group 1: Fundraising Details - The total amount to be raised through the share issuance is capped at 700 million yuan, including the principal [1] - The net proceeds will be allocated to specific projects and to supplement working capital [1] Group 2: Investment Projects - The funds will be invested in the MEMS device optical system manufacturing project [1] - The funds will also support the industrialization of semiconductor process bonding prism projects [1]

Group 1 - The company Meidike (688079) disclosed a plan on December 1 to issue A-shares to specific targets, aiming to raise no more than 700 million yuan [1] - The raised funds will be allocated to the manufacturing project of MEMS device optical systems, the industrialization project of semiconductor process bonding prisms, and to supplement working capital [1]

Group 1 - The core point of the article is that Meidike (688079.SH) announced a plan to issue A-shares to specific targets, aiming to raise a total of no more than RMB 700 million [1] - The net proceeds from the issuance, after deducting issuance costs, are intended to be invested in three main projects: MEMS device optical system manufacturing project, semiconductor process bonding prism industrialization project, and supplementing working capital [1]